Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Sravan Kumar Emany Sells 11,001 Shares

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CFO Sravan Kumar Emany sold 11,001 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the sale, the chief financial officer now owns 309,572 shares of the company’s stock, valued at $1,263,053.76. This trade represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ironwood Pharmaceuticals Trading Down 7.6 %

IRWD traded down $0.29 during mid-day trading on Wednesday, hitting $3.52. 1,613,600 shares of the stock were exchanged, compared to its average volume of 2,892,309. The company has a market cap of $563.31 million, a PE ratio of -127.00 and a beta of 0.47. The firm’s fifty day moving average is $4.27 and its two-hundred day moving average is $5.39. Ironwood Pharmaceuticals, Inc. has a 1-year low of $3.51 and a 1-year high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business’s quarterly revenue was down 19.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.12 earnings per share. As a group, research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. KBC Group NV boosted its position in shares of Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,198 shares in the last quarter. CWM LLC boosted its position in shares of Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after buying an additional 2,345 shares in the last quarter. Wolverine Trading LLC acquired a new stake in Ironwood Pharmaceuticals in the 3rd quarter valued at about $51,000. Diversified Trust Co acquired a new position in Ironwood Pharmaceuticals during the third quarter worth about $52,000. Finally, Legacy Capital Group California Inc. purchased a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at about $59,000.

Analyst Ratings Changes

Several research firms recently issued reports on IRWD. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. StockNews.com lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Craig Hallum lowered their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Leerink Partners initiated coverage on Ironwood Pharmaceuticals in a research note on Monday, September 9th. They issued a “market perform” rating and a $5.00 price target on the stock. Finally, Wells Fargo & Company cut their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.40.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.